Australia markets closed

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
1.1000-0.1500 (-12.00%)
At close: 04:00PM EDT
1.0900 -0.01 (-0.91%)
After hours: 07:47PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
8,312
8,312
-14,927
-27,582
-6,523
Depreciation & amortisation
1,191
1,191
1,086
1,118
1,302
Deferred income taxes
-3,092
-3,092
0
0
-
Stock-based compensation
3,448
3,448
2,085
2,375
3,126
Change in working capital
-10,539
-10,539
-12,015
9,901
-27,130
Accounts receivable
-428
-428
-1,194
-1,032
2,091
Inventory
-2,241
-2,241
1,150
-4,872
-4,927
Other working capital
-2,467
-2,467
-25,628
-11,744
-26,761
Other non-cash items
-600
-600
-689
3,090
3,641
Net cash provided by operating activities
-1,318
-1,318
-25,000
-10,285
-26,106
Cash flows from investing activities
Investments in property, plant and equipment
-1,149
-1,149
-628
-1,459
-655
Purchases of investments
-20,420
-20,420
-16,000
-37,835
-20,000
Sales/maturities of investments
5,000
5,000
11,000
57,835
0
Other investing activities
-142
-142
593
327
703
Net cash used for investing activities
-16,711
-16,711
-5,035
18,921
-19,952
Cash flows from financing activities
Debt repayment
0
0
0
-34,122
-215
Common stock issued
23,954
23,954
8,236
46,200
46,210
Net cash used provided by (used for) financing activities
24,666
24,666
8,238
12,078
46,467
Net change in cash
6,523
6,523
-21,874
20,720
473
Cash at beginning of period
17,111
17,111
38,985
18,265
17,792
Cash at end of period
23,634
23,634
17,111
38,985
18,265
Free cash flow
Operating cash flow
-1,318
-1,318
-25,000
-10,285
-26,106
Capital expenditure
-1,149
-1,149
-628
-1,459
-655
Free cash flow
-2,467
-2,467
-25,628
-11,744
-26,761